KR20170040338A - 안드로겐 박탈 요법 연관 증상의 치료 - Google Patents

안드로겐 박탈 요법 연관 증상의 치료 Download PDF

Info

Publication number
KR20170040338A
KR20170040338A KR1020177006425A KR20177006425A KR20170040338A KR 20170040338 A KR20170040338 A KR 20170040338A KR 1020177006425 A KR1020177006425 A KR 1020177006425A KR 20177006425 A KR20177006425 A KR 20177006425A KR 20170040338 A KR20170040338 A KR 20170040338A
Authority
KR
South Korea
Prior art keywords
day
dose
treatment
rats
males
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177006425A
Other languages
English (en)
Korean (ko)
Inventor
찰스 토마스 벤슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20170040338A publication Critical patent/KR20170040338A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
KR1020177006425A 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료 Ceased KR20170040338A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11
US62/049,192 2014-09-11
PCT/US2015/048801 WO2016040234A1 (en) 2014-09-11 2015-09-08 Treatment of androgen deprivation therapy associated symptoms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187010670A Division KR102024493B1 (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료

Publications (1)

Publication Number Publication Date
KR20170040338A true KR20170040338A (ko) 2017-04-12

Family

ID=54151401

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020177006425A Ceased KR20170040338A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020227032523A Active KR102619415B1 (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020217019807A Ceased KR20210083370A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020187010670A Active KR102024493B1 (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020197003498A Ceased KR20190015628A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020227032523A Active KR102619415B1 (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020217019807A Ceased KR20210083370A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020187010670A Active KR102024493B1 (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020197003498A Ceased KR20190015628A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료

Country Status (23)

Country Link
US (4) US10758515B2 (https=)
EP (2) EP3375444A1 (https=)
JP (4) JP6893171B2 (https=)
KR (5) KR20170040338A (https=)
CN (4) CN106794178A (https=)
AP (1) AP2017009795A0 (https=)
AU (2) AU2015315431C1 (https=)
BR (2) BR112017002449B1 (https=)
CA (2) CA3067289C (https=)
EA (2) EA034553B1 (https=)
ES (1) ES2779978T3 (https=)
HK (1) HK1252811A1 (https=)
IL (3) IL279209B2 (https=)
JO (2) JOP20180072A1 (https=)
MA (1) MA45416A (https=)
MX (3) MX391447B (https=)
MY (2) MY195767A (https=)
NZ (1) NZ728612A (https=)
SG (2) SG11201701630VA (https=)
TW (1) TWI616201B (https=)
UA (1) UA120099C2 (https=)
WO (1) WO2016040234A1 (https=)
ZA (1) ZA201802680B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
WO2021151905A1 (en) 2020-01-27 2021-08-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457892A1 (en) * 2003-01-13 2012-05-30 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
CA2653872A1 (en) 2006-05-31 2007-12-06 Glaxo Group Limited Novel heterocyclic compounds
CA2658098A1 (en) * 2006-07-19 2008-01-24 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
BRPI0912394A2 (pt) * 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
US8003689B2 (en) * 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
KR102098606B1 (ko) * 2012-10-31 2020-04-09 후지필름 도야마 케미컬 가부시키가이샤 신규 아민 유도체 또는 그 염
US9920052B2 (en) * 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Also Published As

Publication number Publication date
BR112017002449B1 (pt) 2022-08-09
CA2956514A1 (en) 2016-03-17
AU2018202714A1 (en) 2018-05-17
AU2018202714B2 (en) 2019-06-20
JP7349480B2 (ja) 2023-09-22
SG10201809673RA (en) 2018-12-28
JP6938550B2 (ja) 2021-09-22
AU2015315431A1 (en) 2017-03-09
WO2016040234A1 (en) 2016-03-17
ZA201802680B (en) 2020-08-26
KR20210083370A (ko) 2021-07-06
US20190111039A1 (en) 2019-04-18
EA201891008A2 (ru) 2018-09-28
AU2015315431B2 (en) 2018-03-08
EP3375444A1 (en) 2018-09-19
KR20180041268A (ko) 2018-04-23
JP2019089795A (ja) 2019-06-13
EA201790220A1 (ru) 2017-07-31
ES2779978T3 (es) 2020-08-21
TWI616201B (zh) 2018-03-01
MA45416A (fr) 2019-04-24
US20200390744A1 (en) 2020-12-17
IL258651A (en) 2018-06-28
US10799478B2 (en) 2020-10-13
MX391447B (es) 2025-03-21
CN106794178A (zh) 2017-05-31
CN113651797A (zh) 2021-11-16
US20240148694A1 (en) 2024-05-09
CA3067289A1 (en) 2016-03-17
IL279209B (en) 2022-10-01
US10758515B2 (en) 2020-09-01
IL279209A (en) 2021-01-31
TW201618782A (zh) 2016-06-01
NZ728612A (en) 2018-03-23
KR102024493B1 (ko) 2019-09-23
KR102619415B1 (ko) 2024-01-02
JP2022000432A (ja) 2022-01-04
MX373322B (es) 2020-05-21
MY195767A (en) 2023-02-10
EP3191094A1 (en) 2017-07-19
KR20220132669A (ko) 2022-09-30
US20170172992A1 (en) 2017-06-22
CA3067289C (en) 2023-04-04
CN113521068A (zh) 2021-10-22
IL250291B (en) 2020-09-30
EA034553B1 (ru) 2020-02-19
IL250291A0 (en) 2017-03-30
JP2023145479A (ja) 2023-10-11
AP2017009795A0 (en) 2017-03-31
MX2017003140A (es) 2017-05-23
MY198753A (en) 2023-09-23
JOP20180072A1 (ar) 2019-01-30
BR112017002449A2 (pt) 2017-12-05
JP2017527584A (ja) 2017-09-21
CA2956514C (en) 2023-04-18
IL279209B2 (en) 2023-02-01
EP3191094B1 (en) 2020-02-19
KR20190015628A (ko) 2019-02-13
UA120099C2 (uk) 2019-10-10
AU2015315431C1 (en) 2018-08-02
IL258651B (en) 2021-02-28
JO3609B1 (ar) 2020-08-27
EA033606B1 (ru) 2019-11-08
HK1252811A1 (en) 2019-06-06
BR122018007412B1 (pt) 2022-08-23
CN108440497A (zh) 2018-08-24
SG11201701630VA (en) 2017-03-30
JP6893171B2 (ja) 2021-06-23
EA201891008A3 (ru) 2019-03-29
MX2021014120A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
US20240148694A1 (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508B (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508A1 (en) Treatment of androgen deprivation therapy associated symptoms

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20170308

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170308

Comment text: Request for Examination of Application

PG1501 Laying open of application
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180416

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180425

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180709

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180425

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180709

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180619

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180416

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170308

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20181025

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181005

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180709

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180619

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180425

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180416

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170308

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20181123

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20181025

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20180709

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20200327

Appeal identifier: 2018101004763

Request date: 20181123

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101004763; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20181123

Effective date: 20200327

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20200327

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20181123

Decision date: 20200327

Appeal identifier: 2018101004763